MAMA
The MAMA Study is designed to find out whether it is better for women who have inflammatory arthritis and are pregnant to temporarily stop or to continue taking biologic medications.
Currently both continuing and stopping using biologics beyond 28 weeks of pregnancy are routine practice in the UK; this varies between different hospitals around the UK. The MAMA Study is looking to provide an answer on which is the better approach.
Key MAMA information:
- Women who take part in the study will be randomly allocated to either continue taking their biologic throughout pregnancy, or to stop by 28 weeks gestation
- We will collect information about participants and their babies
- This study is being run in 35 hospitals in the UK
- The study will run for about 4 years
How can I take part in MAMA?
If you would like more information or are interested in taking part in the MAMA Study, please get in touch with the team at the MAMA Co-ordinating Centre.
About Us
MAMA is coordinated by the National Perinatal Epidemiology Unit Clinical Trial Unit (NPEU CTU) at the University of Oxford and is funded by the National Institute of National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) programme.
